Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 202

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 202
---
 and 30 days from the date that shareholder approval of both merging companies was obtained.

Anti-takeover measures

The Companies Law allows
us to create and issue shares having rights different from those attached to our Ordinary Shares, including shares providing certain
preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this
offering, no preferred shares will be authorized under our amended and restated articles of association. In the future, if we do authorize,
create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to
it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium
over the market value of their Ordinary Shares. The authorization and designation of a class of preferred shares will require an amendment
to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the voting power
attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate
and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as
described above in “—Voting Rights.”

Borrowing Powers

Pursuant to the Companies
Law and our amended and restated articles of association to be in effect upon completion of this offering, our board of directors may
exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to
be exercised or taken by our shareholders, including the power to borrow money for company purposes.

Changes in Capital

Our amended and restated
articles of association to be in effect upon completion of this offering enable us to increase or reduce our share capital. Any such
change is subject to Israeli law and must be approved by a resolution duly passed by our shareholders at a general meeting. In
addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of
sufficient retained earnings or profits, may require the approval of both our board of directors and an Israeli court.

Transfer Agent and Registrar

The transfer agent and
registrar for our Ordinary Shares is . Its
address is , and its telephone number is
.

Listing

We have applied to have our
Ordinary Shares listed on the Nasdaq Capital Market under the symbol “RGNT”. No assurance can